Immatics N.V. (NASDAQ: IMTX)
$7.6000
+0.0200 ( +0.13% ) 209.0K
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.